Yayınlanmış 1 Ocak 2018
| Sürüm v1
Dergi makalesi
Açık
Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial
Yazarlar/Oluşturanlar
- 1. Charite Univ Med Berlin, Dept Neonatol, Berlin, Germany
- 2. Ankara Univ, Childrens Hosp, Sch Med, Div Neonatol, Ankara, Turkey
- 3. Univ Spital Zurich, Dept Neonatol, Zurich, Switzerland
- 4. Hadassah Med Ctr, Dept Neonatol, Jerusalem, Israel
Açıklama
Introduction Retinopathy of prematurity (ROP) is a disease observed in extremely premature infants characterised by visioning-threatening retinal vessel proliferation. Propranolol, a drug used for decades in newborn infants with heart diseases, hypertension and thyrotoxicosis and licenced for infantile haemangiomas, may be effective in halting progression of ROP to severe stages, as suggested by preliminary data from small studies.
Dosyalar
bib-44ccb5b5-e202-4161-a930-cbc9bef40228.txt
Dosyalar
(197 Bytes)
| Ad | Boyut | Hepisini indir |
|---|---|---|
|
md5:3737f1de6a635c8fd8a625a1968cbfc3
|
197 Bytes | Ön İzleme İndir |